The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club

• Published in: Osteoporosis international Vol. 27; no. 7; pp. 2181 - 2195
• Main Authors: Cavalier, E., Bergmann, P., Bruyère, O., Delanaye, P., Durnez, A., Devogelaer, J.-P., Ferrari, S. L., Gielen, E., Goemaere, S., Kaufman, J.-M., Toukap, A. Nzeusseu, Reginster, J.-Y., Rousseau, A.-F., Rozenberg, S., Scheen, A. J., Body, J.-J.
• Format: Journal Article Web Resource
• Language: English
• Published: London Springer London 01-07-2016; Springer Nature B.V; Springer
• Subjects: Belgium; Biochemical markers; Biomarkers; Biomarkers - analysis; Bone; Bone Density; Bone diseases; Bone Diseases, Metabolic - diagnosis; Bone Neoplasms; Bone Remodeling; Bone turnover; Consensus; Endocrinology; Female; Geriatrics; Human health sciences; Humans; Laboratory medicine & medical technology; Lactation; Male; Medicine; Medicine & Public Health; Metabolism; Metastases; Médecine de laboratoire & technologie médicale; Orthopedics; Osteoporosis; Osteoporosis - diagnosis; Osteoporosis, Postmenopausal - diagnosis; Position Paper; Post-menopause; Pregnancy; Renal failure; Renal Insufficiency, Chronic; Rheumatology; Sciences de la santé humaine; Biomarkers; Osteoporosis; Bone
• ISSN: 0937-941X; 1433-2965; 1433-2965
• DOI: 10.1007/s00198-016-3561-3

The exact role of biochemical markers of bone turnover in the management of metabolic bone diseases remains a topic of controversy. In this consensus paper, the Belgian Bone Club aimed to provide a state of the art on the use of these biomarkers in different clinical or physiological situations like in postmenopausal women, osteoporosis in men, in elderly patients, in patients suffering from bone metastasis, in patients with chronic renal failure, in pregnant or lactating women, in intensive care patients, and in diabetics. We also gave our considerations on the analytical issues linked to the use of these biomarkers, on potential new emerging biomarkers, and on the use of bone turnover biomarkers in the follow-up of patients treated with new drugs for osteoporosis.